Lack of disease control remains a major barrier to transplant for older patients with AML
Bone Marrow Transplant
.
2023 Sep;58(9):1054-1056.
doi: 10.1038/s41409-023-02022-3.
Epub 2023 Jun 23.
Authors
Mark Y Jeng
1
,
Denice Kong
2
,
Raja Rajalingam
2
,
Richard J Lin
3
,
Rebecca L Olin
4
Affiliations
1
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
2
Immunogenetics and Transplantation Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
3
Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
[email protected]
.
PMID:
37353571
PMCID:
PMC11022831
DOI:
10.1038/s41409-023-02022-3
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / therapy
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States